Pill Identifier App

Eribulin Pregnancy and Breastfeeding Warnings

Eribulin is also known as: Halaven

Eribulin Pregnancy Warnings

-Animal studies have revealed evidence of fetal harm including embryofetal death, abortion, reduced fetal weight, minor skeletal anomalies, and severe external or soft tissue malformations such as the absence of a lower jaw, tongue, stomach, and spleen. Maternotoxicity has occurred in rats at or above the recommended human dose including splenomegaly, reduced maternal weight gain, and decreased food consumption. -There are no controlled data in human pregnancy. -If this drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. AU TGA pregnancy category D: Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details. US FDA pregnancy category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug is only recommended for use during pregnancy when there are no alternatives and the benefit outweighs the risk. AU TGA pregnancy category: D US FDA pregnancy category: D Comments: Women of childbearing age should be advised to avoid becoming pregnant while they or their male partner are receiving this drug and should use effective contraception during and up to 3 months after treatment.

Eribulin Breastfeeding Warnings

AU, UK: Use is contraindicated. US: A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother. Excreted into human milk: Unknown Excreted into animal milk: Unknown The effects in the nursing infant are unknown.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web4)